.Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J05A_DirectActingAntivirals.J05AR28_StavudineAndLamivudine.StavudineAndLamivudine .Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J05A_DirectActingAntivirals.J05AR28_StavudineAndLamivudine.StavudineAndLamivudine| name: | StavudineAndLamivudine |
| ATC code: | J05AR28 | route: | oral |
| n-compartments | 1 |
Stavudine and lamivudine are nucleoside reverse transcriptase inhibitors (NRTIs) used in combination for the treatment of HIV-1 infection. The fixed-dose combination is classified under ATC code J05AR28 and is intended to suppress viral replication in HIV-positive individuals. Both drugs are approved and used within antiretroviral therapy regimens but have largely been replaced by newer, less toxic alternatives in high-income settings. The fixed-dose combination may still be used in resource-constrained settings.
No published population pharmacokinetic studies found for the fixed-dose combination of stavudine and lamivudine. Below are rough estimated parameters based on published PK data for the individual drugs in healthy adults after oral administration.